RecruitingNCT07132333
Molecular Inflammation Board at the Center for Personalized Medicine
The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study
Sponsor
University Hospital Tuebingen
Enrollment
3,000 participants
Start Date
Nov 16, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
Molecular Inflammation Board at the Center for Personalized Medicine
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Chronic inflammatory disorder (PsO, PsA, SpA, IBD)
- Given informed consent
- years of age
Exclusion Criteria1
- No capacity to consent
Interventions
BIOLOGICALBiologic Agent
Intervention with biologic agents
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07132333
Related Trials
ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool
NCT068105183 locations
Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
NCT074019921 location
Study on the Use of Traditional Chinese Medicine Diagnostic Tools to Assist in Identifying the Clinical Characteristics of Inflammatory Bowel Disease and Research on Metabolic Plastids of Tongue Coating
NCT073141511 location
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
NCT070214958 locations